[Infostock Daily=Reporter Park Jeong-Do] Samsung BioLogics announced on the 17th that it has signed a contract with Panoros Bioscience for the development of a contract for PB101, a candidate for anticancer drugs.
Samsung BioLogics plans to provide pre-CDO (pre-clinical) services such as process development, clinical sample production and support for submission of clinical trial plans (IND), and pre-clinical and clinical substance production from the development of cell lines of PB101.
PB101 is a target of all the genera of VEGF, an neovascularization factor that is overexpressed around cancer cells, and acts to inhibit the growth of cancer cells.
PB101 is a substance that requires a high level of research because of its complex protein structure. Samsung Bio Logics has established a customized strategy for PB101 development
Reporter Park Jeong-Do newface0301@naver.com